<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest update is out from Ab&amp;B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ). Ab&amp;B Bio-Tech CO., LTD. JS plans to abolish its Supervisory Committee and transfer its statutory oversight functions to the Board’s Audit Committee, a move that aligns the company’s governance structure with its operational needs and the latest requirements of PRC company law. The change would also terminate existing supervisor positions and streamline internal oversight processes, subject to shareholder approval at a forthcoming general meeting. The company will amend its Articles of Association to reflect the removal of the Supervisory Committee, update provisions in line with new regulatory standards, and perform textual and structural clean-up. In parallel, Ab&amp;B Bio-Tech has reconstituted its Strategy Committee, appointing chairman An Youcai alongside members He Yiming and Li Xiangming, signaling a refreshed strategic governance framework at board level. More about Ab&amp;B Bio-Tech CO., LTD. JS Class H Ab&amp;B Bio-Tech CO., LTD. JS is a mainland China-based joint stock company listed in Hong Kong, operating in the biotechnology sector. Through its group structure, it focuses on bio-tech products and related services, positioning itself within the broader life sciences and healthcare supply chain in the Chinese and regional markets. Average Trading Volume: 740,312 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$11.54B Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.</div>

02627

588130

516500

Ab&B Bio-Tech CO., LTD. JS plans to abolish its Supervisory Committee and transfer oversight functions to the Board’s Audit Committee, aligning governance with operational needs and PRC company law. This change, subject to shareholder approval, will streamline internal oversight and amend the Articles of Association. Additionally, the company has reconstituted its Strategy Committee, appointing An Youcai as chairman, indicating a refreshed governance framework. Ab&B Bio-Tech operates in the biotechnology sector and is listed in Hong Kong, focusing on bio-tech products and services in the life sciences and healthcare supply chain.

Tip Ranks

AB&B BIO-TECH-B

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Ab&B Bio-Tech to Scrap Supervisory Committee and Revamp Governance Framework